Why the study?
Are serum S100A8, S100A9, and S100A12 levels associated with acute coronary syndrome in patients undergoing coronary angiography?
Population
90 patients who underwent coronary angiography and/or percutaneous coronary interventions, categorized into…
Comparison
Measurement of serum S100A8, S100A9, and S100A12… vs Comparison between patients with normal coronary…
Design
Cross-sectional
Key result
Serum S100A12 levels were significantly elevated in acute coronary syndrome compared to normal coronary arteries and stable CAD (p=0.001), and independently associated with ACS (p=0.002).
Authors
Loading...
May support S100A12 as ACS biomarker candidate; leaves open clinical utility pending prospective validation.
Observational (n=90)
Are serum S100A8, S100A9, and S100A12 levels associated with acute coronary syndrome in patients undergoing coronary angiography?
p-value: p=0.002
Serum S100A12 is significantly elevated in patients with acute coronary syndrome and may serve as a biomarker for coronary plaque instability.
Büyükterzi et al. (2017) conducted an observational in Acute coronary syndrome (n=90). Serum S100A8, S100A9, and S100A12 levels vs. Normal coronary arteries and stable coronary artery disease was evaluated on Association with acute coronary syndrome (p=0.002). Serum S100A12 levels were significantly elevated in acute coronary syndrome compared to normal coronary arteries and stable CAD (p=0.001), and independently associated with ACS (p=0.002).